North Carolina based Biomarck Pharmaceuticals has received FDA allowance to begin human trials for their patented compound BIO-11006, for adults with lung cancer. Discovered by Dr Ken Adler at North Carolina State Universityworking in partnership with Biomarck, inhaled Bio-11006 has demonstrated effectiveness on human cell cultures and animals in the laboratory. It demonstrated impressive results in adult tumours and childhood cancers, specifically, Rhabdomyosarcoma, Neuroblastoma and Osteosarcoma in children.http://bit.ly/2q4N0eO